Histogenics Corporation (HSGX) Scheduled to Post Earnings on Thursday
Histogenics Corporation (NASDAQ:HSGX) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, November 9th. Analysts expect Histogenics Corporation to post earnings of ($0.28) per share for the quarter.
Histogenics Corporation (NASDAQ:HSGX) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.06. During the same quarter last year, the business earned ($0.61) earnings per share. On average, analysts expect Histogenics Corporation to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Histogenics Corporation (NASDAQ HSGX) opened at $2.12 on Wednesday. Histogenics Corporation has a twelve month low of $1.45 and a twelve month high of $2.54.
Several equities research analysts have commented on HSGX shares. ValuEngine downgraded shares of Histogenics Corporation from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Zacks Investment Research downgraded shares of Histogenics Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, August 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.50 target price on shares of Histogenics Corporation in a research note on Thursday, November 2nd.
TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/08/histogenics-corporation-hsgx-scheduled-to-post-earnings-on-thursday.html.
About Histogenics Corporation
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Stock Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related stocks with our FREE daily email newsletter.